Summary of vaccine responses.

<p>Summary of vaccine responses.</p

Multivariable model of seroconversion within those vaccinated in risk groups (chronic disease and/or immunocompromised).

<p>Multivariable model of seroconversion within those vaccinated in risk groups (chronic disease and/or immunocompromised).</p

Distribution of fold responses pre to post Pandemrix™ vaccination by 2009 seasonal influenza vaccination status.

<p>Distribution of fold responses pre to post Pandemrix™ vaccination by 2009 seasonal influenza vaccination status.</p

Summary of cohort for analysis.

<p>Summary of cohort for analysis.</p

Estimation of the interval to seroconversion.

<p>a) Proportion of individuals with HI titer <32 by interval since symptom onset: blue lines and points show the proportion in four-day intervals with confidence intervals and the red curve show the fitted parametric inverse cumulative distributions with the 95% CI (credible intervals) and b) distribution of the time to seroconversion since symptoms with 95% CI.</p

Changes in seroprevalence and cumulative incidence over time.

<p>Estimated changes in seroprevalence and cumulative incidence compared with proportion with HI titer ≥32 by week by age group a) 1–4 years, b) 5–14 years c) 15–24 years d) 25–44 years.</p

Baseline percentage of samples with HI titer ≥32 before the start of the second wave, number of samples tested and estimated cumulative incidence (with 95% credible intervals) over the second wave of H1N1 (2009) infection in England starting from September 1^st 2009 according to age group.

<p>*CI, credible intervals,</p><p>**as described in reference 6.</p

Posterior distribution of the cumulated incidences.

<p>Estimated cumulated incidence distributions for age-groups 1–4, 5–14, 15–24, 25–44 years during the second wave.</p

Proportion of clinial cases by week.

<p>Proportion of clinical cases by week for the second wave for four age-groups (1–4, 5–14, 15–24, 25–44 years) derived from clinical surveillance data.</p

The antibody secreting cell response induced after influenza vaccination.

<p>Lymphocytes were collected 7 days after the first (day 7) and second vaccine dose (day 28) of inactivated virosomal H5N1 vaccine alone or formulated 1.5, 7.5 or 30μg HA formulated with Matrix-M (50μg). The influenza-specific IgG, IgA and IgM antibody secreting cells (ASC) were enumerated using the ELISPOT assay. The data are presented as the mean number of influenza-specific ASC per 200 000 lymphocytes ± standard error of the mean to the homologous vaccine strain A/Vietnam/1104/2004 (NIBRG-14), and the heterologous responses to A/Turkey/Turkey/1/05 (NIBRG-23), A/Cambodia/R0405050/2007 (NIBRG-88) and A/Anhui/1/05 (RG6). Statistical differences between the adjuvanted and non-adjuvanted groups were calculated by ANOVA with Dunnett’s multiple comparisons test. *p<0.05.</p